Celsion Corporation Advances Proof of Concept to Non-human Primate Challenge Study Against SARS-CoV-2 with In-Process Vaccine Candidate

<p>Preclinical results demonstrate safe and efficient immune response with vaccine development showing promise of neutralizing activity for a range of variants LAWRENCEVILLE, N.J., Jan. 31, 2022 (GLOBE NEWSWIRE) — Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation DNA-based vaccines, announces it has engaged BIOQUAL, Inc., a preclinical testing contract …</p>
<p>The post <a rel="nofollow" href="https://forextv.com/top-news/celsion-corporation-advances-proof-of-concept-to-non-human-primate-challenge-study-against-sars-cov-2-with-in-process-vaccine-candidate/">Celsion Corporation Advances Proof of Concept to Non-human Primate Challenge Study Against SARS-CoV-2 with In-Process Vaccine Candidate</a> appeared first on <a rel="nofollow" href="https://forextv.com">ForexTV</a>.</p>